Interventions for Tuberculosis Control and Elimination 2002

563. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations
and the treatment of tuberculous meningitis.
650-5.
Am Rev Respir Dis 1993; 148:
564. D’Oliveira JJG. Cerebrospinal fluid concentrations of rifampin in meningeal
tuberculosis. Am Rev Respir Dis 1972; 106: 432-7.
565. Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis
drugs. Clin Pharmacokinetics 1985; 10: 532-4.
566. Place VA, Pyle MM, de la Huerga J.
Am Rev Respir Dis 1969; 99: 783-5.
Ethambutol in tuberculous meningitis.
567. Bobrowitz ID. Ethambutol in tuberculous meningitis. Chest 1972; 61: 629-32.
568. Holdiness MR. Management of tuberculosis meningitis. Drugs 1990; 39: 224-33.
569. Hughes IE, Smith H, Kane PO. Ethionamide: its passage into the cerebrospinal
fluid in man. Lancet 1962; 1: 616-2.
570. Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children
with tuberculous meningitis. J Pediatr 1989; 115: 483-6.
571. Humphries M. The management of tuberculous meningitis. (Editorial). Thorax
1992; 47: 577-81.
572. Visudhiphan P, Chiemchanya S. Evaluation of rifampicin in the treatment of
tuberculous meningitis in children. J Pediatr 1975; 87: 983-6.
573. Donald PR, Schoeman JF, Van Zyl LE, de Villiers JN, Pretorius M, Springer P.
Intensive short course chemotherapy in the management of tuberculous meningitis.
Int J Tuberc Lung Dis 1998; 2: 704-11.
574. Kole HM. Thiacetazone-induced hypersensitivity. (Correspondence). Lancet
1991; 338: 583-4.
575. Pozniak AL, MacLeod GA, Mahari M, Legg W, Weinberg J. The influence of
HIV status on single and multiple drug reactions to antituberculous therapy in
Africa. AIDS 1992; 6: 809-14.
576. Grosset JH. Treatment of tuberculosis in HIV infection. Tubercle Lung Dis
1992; 73: 384-7.
577. Okwera A, Johnson JL, Vjecha MJ, Wolski K, Whalen CC, Hom D, Huebner R,
Mugerwa RD, Ellner JJ. Risk factors for adverse drug reactions during thiacetazone
treatment of pulmonary tuberculosis in human immunodeficiency virus
infected adults. Int J Tuberc Lung Dis 1997; 1: 441-5.
578. Chaisson RE, Schecter GF, Theuer CP, Rutherford GW, Echenberg DF,
Hopewell PC. Tuberculosis in patients with the acquired immunodeficiency syndrome.
Clinical features, response to therapy, and survival. Am Rev Respir Dis
1987; 136: 570-4.
579. Jones BE, Otaya M, Antoniskis D, Sian S, Wang F, Mercado A, Davidson PT,
Barnes PF. A prospective evaluation of antituberculosis therapy in patients with
human immunodeficiency virus infection.
150: 1499-502.
Am J Respir Crit Care Med 1994;
207